Annarita Tagliaferri

Dr
Regional Reference Center for Inherited Bleeding Disorders, University Hospital of Parma

Presentation(s):

• OC 27.4 - Recombinant factor VIII Fc showed better prophylactic effectiveness compared to standard half-life factor VIII in haemophilia A - results from A-SURE, a 24-month prospective, non-interventional study

  Sunday, July 10, 2022
  3:30 PM – 3:45 PM

• VPB1165 - IDEAL study: A real-world assessment of pattern of use and clinical outcomes with recombinant factor IX albumin fusion protein (rIX-FP) in patients with haemophilia B in Italy

  Tuesday, July 12, 2022
  6:30 PM – 7:30 PM